MN

Fluorescence in Situ Hybridization for the Detection of Lung Cancer

Funded by LUNGevity Foundation in collaboration with The CHEST Foundation, the philanthropic arm of the American College of Chest Physicians
Clinton H. Doerr, MD
Mayo Graduate School of Medicine
Rochester

Tests that improve the ability to detect tumors at their earliest stages have the potential to reduce lung cancer mortality. Dr. Doerr developed three fluorescence in situ hybridization (FISH) probe sets for the detection of lung cancer in cell specimens. His research is assessing the reliability of these probe sets and routine cell examination for the detection of lung cancer in cell specimens obtained from bronchoscopy.

The Role of alpha9beta1 Integrin in Modulating Pulmonary Angiogenesis

Funded equally by LUNGevity Foundation and American Lung Association National Office
Nicholas Vlahakis, MD
Mayo Clinic
Rochester

Angiogenesis is the process by which cancer cells recruit blood vessels to the tumor. This aids the growth of cancer cells by providing nutrition and oxygen to them. Dr. Vlahakis is studying how a protein called VEGF-A interacts with certain proteins expressed on the surface of lung cells to control the angiogenesis process.

Transposon Mutagenesis for Lung Cancer Gene Discovery

Funded equally by LUNGevity Foundation and the Illinois Chapter of the American Cancer Society
Timothy K. Starr, PhD
University of Minnesota Department of Genetics, Cell Biology and Development
Minneapolis

In order to identify mutated genes that cause lung cancer, Dr. Starr has developed a system that is capable of randomly mutating genes within cells, resulting in tumor formation. The genes mutated by this method can easily be identified using standard molecular biology techniques. He can then test their role in lung cancer formation. 

Surgery versus SBRT for patients with lung cancer and limited pulmonary function

Funded equally by LUNGevity Foundation and The CHEST Foundation
Dennis A. Wigle, MD, PhD
Mayo Clinic Cancer Center
Rochester

Dr. Wigle is investigating the effectiveness of stereotactic radiation therapy (SBRT) versus surgery in patients with compromised pulmonary function. This project is a phase II clinical trial whose results will set the stage for more-definitive phase III trials.